Drugs for Disorders of Calcium Balance

Classification

Bisphosphonates: alendronate, risedronate, zoledronic acid, pamidronate. Calcitonin. Denosumab(RANKL inhibitor). PTH analogue: teriparatide. Vitamin D: cholecalciferol, calcitriol. Calcimimetic: cinacalcet. Calcium salts.

Organizing Framework: RANK/RANKL/OPG

Osteoblasts express RANKL → binds RANK on osteoclast precursors → differentiation into resorbing osteoclasts. Osteoblasts also secrete OPG(decoy receptor, binds RANKL, blocks RANK activation). RANKL:OPG balance(regulated by PTH, vitamin D, estrogen) = determines net resorption rate. Most drugs here act on THIS specific axis at different points.

Mechanism

Bisphosphonates: bind bone mineral(hydroxyapatite) at active remodelling sites, taken up specifically by RESORBING osteoclasts → nitrogen-containing types(alendronate, risedronate, zoledronic acid) inhibit farnesyl pyrophosphate synthase(mevalonate pathway, needed for GTPase prenylation) → osteoclast loses ruffled border function → APOPTOSIS → ↓resorption. Bone-targeted delivery = LONG skeletal duration(months-years, released only when that site remodels again) despite SHORT plasma t½. Poor oral bioavailability(<1%) → empty stomach+plain water+upright 30-60min(↓oesophageal irritation risk).

Calcitonin(salmon, therapeutic): inhibits osteoclast activity directly via osteoclast receptors + SEPARATE analgesic effect in BONE PAIN(distinct property, useful in vertebral compression fractures). Weaker than bisphosphonates + TACHYPHYLAXIS(receptor downregulation) limits long-term primary use → 2nd-line/pain-targeted.

Denosumab: monoclonal antibody vs RANKL ITSELF — neutralizes before RANK engagement, MOST UPSTREAM point of axis. NOT stored in bone(unlike bisphosphonates) → effect wanes QUICKLY off dosing → REBOUND ↑bone turnover+vertebral fracture risk if discontinued without transitioning to another antiresorptive — HIGH-YIELD, sharply distinguishes from bisphosphonate discontinuation profile.

Teriparatide: recombinant PTH(1-34). PARADOX: INTERMITTENT/PULSATILE PTH = ANABOLIC(net bone-forming, ↑osteoblast activity more than osteoclast) vs CONTINUOUS PTH elevation(chronic hyperparathyroidism) = CATABOLIC(net resorptive) — IDENTICAL pulsatile-vs-continuous paradox as GnRH agonists(Pituitary Hormones), different hormone/receptor system, same principle. Reserved severe osteoporosis(cost + theoretical osteosarcoma risk, animal-model — duration capped ~2yr).

Vitamin D: ↑intestinal Ca2+/phosphate absorption(dominant action) + required for normal mineralization. Deficiency → RICKETS(children)/OSTEOMALACIA(adults)(undermineralized weak bone — DISTINCT from osteoporosis’s normal-mineralization-but-reduced-quantity, frequently tested distinction). Calcitriol = already-activated form(1,25-(OH)2D), bypasses renal 1α-hydroxylation → useful in CKD(kidney’s own activation impaired, cholecalciferol less reliable here).

Cinacalcet: calcimimetic — allosterically sensitizes parathyroid CaSR to circulating calcium → parathyroid “perceives” higher Ca2+ than actual → ↓PTH secretion. Secondary hyperparathyroidism in CKD + parathyroid carcinoma. Genuinely distinct receptor-SENSITIZATION mechanism from everything else here.

Adverse Effects

Bisphosphonates: oesophagitis/ulceration(administration issue) + 2 PAIRED serious long-term risks(SAME underlying theme: excessive suppression of bone turnover): osteonecrosis of the jaw(esp with dental procedures, impaired remodelling at high-stress site) + atypical femoral fractures(subtrochanteric/diaphyseal, DIFFERENT from typical osteoporotic sites — accumulated microdamage impaired remodelling can’t repair). Both = “too much suppression of the process needed for bone health,” counterintuitive for a fracture-prevention drug.

Denosumab: hypocalcaemia(predictable, potent resorption suppression — needs adequate Ca2+/vit D during therapy) + rebound-fracture-on-discontinuation(above). SHARES ONJ+atypical fracture risk with bisphosphonates(same “excessive suppression” theme, different specific mechanism).

Teriparatide: hypercalcaemia(net resorption if overdosed/mistimed) + theoretical osteosarcoma(duration limit).

Vitamin D excess: hypercalcaemia+hypercalciuria(nephrolithiasis) — dose-related, distinct from deficiency’s very different picture.

Clinical Relevance

RANK/RANKL/OPG framework + pulsatile-vs-continuous paradox(recurring IDENTICALLY from GnRH agonists) = what connects this topic’s mechanisms genuinely, not arbitrary list. Bisphosphonates/denosumab/teriparatide all act on SAME osteoblast-osteoclast balance at DIFFERENT points(intracellular osteoclast enzyme; upstream RANKL signal; osteoblast stimulation) — correctly predicts BOTH relative potency/onset differences AND genuinely distinct discontinuation/toxicity profiles, not one undifferentiated “antiresorptive” category.

Classification

Bisphosphonates: alendronate, risedronate, zoledronic acid, pamidronate
Calcitonin
Denosumab (RANKL inhibitor)
Parathyroid hormone analogues: teriparatide
Vitamin D and analogues: cholecalciferol, calcitriol
Calcimimetics: cinacalcet
Calcium salts

The Physiological Framework: Osteoblasts, Osteoclasts, and the RANK/RANKL/OPG System

Bone remodelling is a continuous balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption — nearly every drug in this topic acts by shifting this balance in one direction, making the osteoblast/osteoclast framework, and specifically the RANK/RANKL/osteoprotegerin (OPG) signalling system, the organizing concept for the whole topic. Osteoblasts express RANKL (receptor activator of nuclear factor-κB ligand), which binds RANK on osteoclast precursors, promoting their differentiation into mature, bone-resorbing osteoclasts; osteoblasts also secrete OPG, a decoy receptor that binds RANKL and prevents it from activating RANK — the relative balance of RANKL versus OPG production (itself regulated by numerous hormones, including PTH, vitamin D, and estrogen) determines the net rate of osteoclast formation and bone resorption, and several drugs in this topic act directly on this specific signalling axis.

Mechanism of Action

Bisphosphonates: bind avidly to bone mineral (hydroxyapatite) at sites of active remodelling, and are taken up specifically by osteoclasts during resorption — once internalized, nitrogen-containing bisphosphonates (alendronate, risedronate, zoledronic acid — the modern, more potent generation) inhibit farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway required for prenylation (a lipid modification) of small GTPase proteins essential for osteoclast cytoskeletal function and survival — without functional prenylated GTPases, the osteoclast cannot maintain its ruffled border (the specialized resorptive membrane) and undergoes apoptosis, reducing bone resorption. This bone-mineral-targeting delivery mechanism (concentrating specifically where remodelling is occurring) is why bisphosphonates achieve a genuinely long duration of skeletal action (months to years after the last dose, since bound drug is released only as that specific bone site is eventually remodelled again) despite a very short plasma half-life. Poor oral bioavailability (under 1%) means oral bisphosphonates must be taken on an empty stomach with plain water, remaining upright for 30–60 minutes afterward — a specific, practically important administration instruction directly tied to both poor absorption generally and a genuine oesophageal irritation risk if the tablet lingers in contact with oesophageal mucosa.

Calcitonin: (from thyroid parafollicular C-cells, the natural physiological hormone, used therapeutically as salmon calcitonin given its greater potency/longer action than human calcitonin) directly inhibits osteoclast activity via calcitonin receptors on the osteoclast itself, and also has a genuine, additional analgesic effect specifically in bone pain (a distinct, mechanistically separate property from its resorption-inhibiting action, exploited in painful vertebral compression fractures) — generally a weaker antiresorptive effect than bisphosphonates, and tachyphylaxis (declining effect with continued use, from receptor downregulation) limits its long-term use as primary osteoporosis therapy, positioning it more as a second-line or specifically pain-targeted option.

Denosumab: a monoclonal antibody against RANKL itself — directly binding and neutralizing RANKL before it can engage RANK, preventing osteoclast differentiation/activation at the most upstream point of the signalling axis described above, a genuinely different, more targeted mechanism than bisphosphonates’ downstream intracellular enzyme inhibition. A specific, important pharmacodynamic distinction from bisphosphonates: denosumab’s effect is not stored in bone (unlike bisphosphonates’ long skeletal retention) — its antiresorptive effect wanes relatively quickly once dosing stops, producing a rebound increase in bone turnover and vertebral fracture risk if discontinued without transitioning to another antiresorptive agent, a specific, high-yield, increasingly-recognized clinical concern distinguishing denosumab’s discontinuation risk profile sharply from bisphosphonates’.

Teriparatide: recombinant human PTH (1-34 fragment) — genuinely paradoxical given PTH’s usual association with bone resorption (see below), but intermittent, pulsatile PTH administration is anabolic (net bone-forming), stimulating osteoblast activity/number more than osteoclast activity when given as a once-daily injection producing a brief PTH spike, in contrast to the continuous PTH elevation of chronic hyperparathyroidism, which is catabolic (net bone-resorbing) — the identical pulsatile-versus-continuous signalling paradox already established for GnRH agonists under Pituitary Hormones, here governing an entirely different hormone/receptor system, worth explicitly recognizing as the same underlying pharmacological principle recurring rather than a separate fact to memorize fresh. Reserved for severe osteoporosis given cost and a theoretical (animal-model-derived, not clearly established in humans at therapeutic exposure) osteosarcoma risk that limits duration of use (generally capped at 2 years).

Vitamin D (cholecalciterol/calcitriol): increases intestinal calcium and phosphate absorption (the dominant action) and, at the bone level, is genuinely required for normal mineralization — vitamin D deficiency causes rickets in children and osteomalacia in adults (undermineralized, structurally weak bone, mechanistically distinct from osteoporosis’s normally-mineralized-but-reduced-quantity bone, a frequently-tested distinction). Calcitriol is the already-activated form (1,25-dihydroxyvitamin D), bypassing the need for renal 1α-hydroxylation — specifically useful in chronic kidney disease, where the kidney’s own activation capacity is impaired, making cholecalciferol (requiring renal activation) less reliably effective in this specific population.

Cinacalcet: a calcimimetic, allosterically sensitizing the parathyroid gland’s calcium-sensing receptor (CaSR) to circulating calcium — making the parathyroid “perceive” calcium levels as higher than they actually are, suppressing PTH secretion — used for secondary hyperparathyroidism in chronic kidney disease and for parathyroid carcinoma, a genuinely distinct receptor-sensitization mechanism from every other drug in this topic.

Adverse Effects

Bisphosphonates: oesophagitis/oesophageal ulceration (from the administration-technique issue above), and two specific, serious, though rare, long-term risks worth learning as a pair given their shared underlying theme (excessive suppression of bone turnover, paradoxically from a drug meant to treat bone disease): osteonecrosis of the jaw (particularly associated with dental procedures during therapy, thought related to impaired bone remodelling capacity at a site of high mechanical/infectious stress) and atypical femoral fractures (a distinctive fracture pattern, in the subtrochanteric/diaphyseal femur rather than the typical osteoporotic fracture sites, thought to reflect accumulated microdamage that impaired remodelling can no longer adequately repair) — both genuinely counterintuitive complications of a drug whose entire purpose is fracture prevention, worth understanding as “too much suppression of the very process needed for bone health/repair,” not a random toxicity.

Denosumab: hypocalcaemia (a predictable consequence of potent resorption suppression, requiring adequate calcium/vitamin D supplementation during therapy) and the rebound-fracture-risk-on-discontinuation already described above; shares osteonecrosis of the jaw and atypical femoral fracture risk with bisphosphonates (same underlying “excessive remodelling suppression” theme despite the different specific mechanism).

Teriparatide: hypercalcaemia (a predictable consequence of net bone resorption exceeding the intended anabolic window if overdosed/mistimed), and the theoretical osteosarcoma signal above limiting duration.

Vitamin D (excess): hypercalcaemia and hypercalciuria (nephrolithiasis risk), a genuinely dose-related toxicity worth distinguishing from deficiency’s very different clinical picture.

Clinical Relevance

The RANK/RANKL/OPG framework and the pulsatile-versus-continuous signalling paradox (recurring identically from GnRH agonists) are what make this topic’s drug mechanisms genuinely connected rather than an arbitrary list — recognizing that bisphosphonates, denosumab, and teriparatide all act on the same fundamental osteoblast-osteoclast balance, just at different points (intracellular osteoclast enzyme, upstream RANKL signal, and osteoblast stimulation respectively) is what correctly predicts both their relative potency/onset differences and their genuinely distinct discontinuation/toxicity profiles, rather than treating “antiresorptive” as a single undifferentiated drug category.

RANK/RANKL/OPG signalling axis with bisphosphonate (intracellular osteoclast enzyme), denosumab (RANKL neutralization), and teriparatide (osteoblast stimulation) each marked at their point of action.
Pulsatile vs continuous PTH exposure producing opposite net effects (anabolic vs catabolic), mirroring the GnRH agonist paradox.